Valproate is now contraindicated in pregnancy and women of child-bearing potential. The new stipulations from the Coordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh), a regulatory body representing European Union member states, about the use of valproate in women of child-bearing potential states that “Valproate should never be started unless alternative treatments are not suitable”. However, people taking this drug used to treat epilepsy should not stop valproate use abruptly, without consulting their doctor. The new regulations are discussed in this podcast by Professor Sanjay Sisodiya (UCL Institute of Neurology, London), who’s the author of a Practical Neurology editorial on this subject (http://pn.bmj.com/content/early/2018/04/19/practneurol-2018-001955). Other related articles in the Practical Neurology website: ►http://pn.bmj.com/content/early/2018/04/19/practneurol-2018-001932 ► http://pn.bmj.com/content/early/2018/04/19/practneurol-2018-001931

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related